Multiple Positive Factors Align as Healthcare Sector Successfully Halts Decline; Healthcare ETF (512170) Closes Higher with Late-Session Rally, Institutions Say Pharma May Be Entering Accumulation Phase

Deep News11-17

On November 17, the healthcare sector, which had been declining for consecutive days, bucked the broader market trend and showed strength. The CSI Medical Index surged more than 1% from negative territory in early trading, pulled back in the afternoon along with the broader market, but ultimately rallied in late trading to close higher, ending a four-day losing streak. The Healthcare ETF Huabao (512170), which tracks the index, successfully recovered its annual moving average. Among constituent stocks, gainers and losers were evenly split. Heavyweight stocks WuXi AppTec, Aier Eye Hospital, and Tigermed rose more than 1%, while Intco Medical gained 5.26%. MGI Tech fell 2.78%, and Pharmaron declined 1.68%. The healthcare sector's counter-trend stabilization may have been driven by three catalysts.

First, the dual medical insurance catalogues have been finalized. On the 14th, the National Healthcare Security Administration officially released the 2026 Basic Medical Insurance Catalogue and the Commercial Insurance Innovative Drug Catalogue, adding 107 new drugs, of which 51 are Class 1 innovative drugs—a record high. The Commercial Insurance Innovative Drug Catalogue added 12 new drugs, bringing the total to 28, effective January 1, 2027. Second, geopolitical pressure has been temporarily lifted. The Biosecure Act, which had long suppressed valuations of the CXO sector, has run its course. WuXi AppTec was officially removed from the 1260H list, marking the formal resolution of a major crisis affecting the position of Chinese CXOs in the global innovative drug supply chain, with global competitiveness expected to further improve. Third, defensive rotation amid broader market weakness. With the market recently weakening, low-position sectors represented by healthcare have highlighted their defensive attributes. The CSI Medical Index's latest price-to-earnings ratio (TTM) stands at only 27.12 times, still below more than 90% of the time range over the past decade, offering compelling allocation value.

The Western Pharmaceutical team noted that during the market's ebb phase, pharma may be entering an accumulation stage, and they are optimistic about "riding the wave" when the next rising tide comes. For one-click tracking of the healthcare market, investors may consider the flagship pharmaceutical and healthcare ETF—Healthcare ETF Huabao (512170): with third-quarter report scale exceeding 24.3 billion yuan. It focuses on medical devices plus healthcare services (with CXO exposure exceeding 30%), while also covering AI healthcare and consumer healthcare. It is also a margin trading target and an ETF Connect target. Off-exchange feeder fund: 012323.

[Data Source] Public information from Shanghai-Hong Kong-Shenzhen exchanges, CSI Index Company, Hang Seng Index Company, etc. Weight data as of October 31, 2026. [Institutional View] Western Pharmaceutical Li Mengyuan, November 15, 2026, "During Market Ebb, Pharma Enters Accumulation Phase, Continue to Favor CXO and Innovative Drugs." [Fund Fee Rates] ETF funds do not charge sales service fees. When investors subscribe or redeem fund shares, the subscription/redemption agent broker may charge a commission not exceeding 0.5%, which includes fees charged by the stock exchange and registration institution. Fund fee rates are detailed in each fund's legal documents. [Special Notice] The risk level of the Healthcare ETF Huabao feeder fund as assessed by the fund manager is R4—medium-high risk, suitable for aggressive (C4) and above investors. The risk level of Healthcare ETF Huabao is R3—medium risk, suitable for balanced (C3) and above investors. [Risk Disclosure] The index constituent stocks mentioned in this article are for illustrative purposes only. Individual stock descriptions do not constitute investment advice of any form, nor do they represent the holdings or trading activities of any fund under the manager. The constituent stocks of the underlying index are adjusted in due course according to the index compilation rules. Any information appearing in this article (including but not limited to individual stocks, commentary, forecasts, charts, indicators, theories, and any form of expression) is for reference only, and investors must be responsible for their own investment decisions. In addition, any views, analyses, and forecasts in this article do not constitute investment advice of any form to readers, nor shall they bear any responsibility for direct or indirect losses caused by the use of the content herein. Fund investment involves risks. Past performance of a fund does not represent its future performance. The performance of other funds managed by the fund manager does not constitute a guarantee of the fund's performance. Fund investment requires caution. MACD golden cross signals have formed; these stocks are performing well!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment